Tag: CLTI
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for below-the-knee arteries
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstr...
TCT 2024: Drug-eluting resorbable scaffold proves cost effective at one year in LIFE-BTK analysis
A retrospective economic analysis of the LIFE-BTK trial has demonstrated the one-year cost-effec...
SCOREPAD seeks to address “alarmingly high” mortality in CLTI patients with underlying coronary disease
A new research letter underscores the need to improve long-term survival following lower extremi...
Abbott’s Esprit BTK scaffold system given US FDA approval for CLTI treatment
Abbott has announced that the US Food and Drug Administration (FDA) has approved the Esprit BTK ever...
Revascularisation considered over amputation for CLTI in UK, new study states
A new study published in BJS Open has found that revascularisation treatment to restore blood fl...
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough for below-the-knee arteries
Results of the LIFE-BTK randomised controlled trial have just been presented at TCT 2023 (23–26 ...
BASIL-2 points towards endovascular-first revascularisation strategy in CLTI patients
A question from Manj Gohel (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) on w...
AHA 2022: First data from BEST-CLI bring surgical bypass into the forefront of discussion for patients with high-quality great saphenous vein
The first results from the BEST-CLI randomised controlled trial (RCT) of 1,830 patients show tha...
